NBG Volume Alert - NBG 2.24 National Bank of Greece Sa $NBG

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
NBG Volume Alert - NBG 2.24 National Bank of Greece Sa $NBG Hit a high of 2.31 Currently 11:15 Last price 2.24 -0.10 -4.27% With a day low of 2.23 and a current volume of 2,029,071.

NBG National Bank of Greece Sa Recent Headline News

National Bank of Greece's (NBG) CEO Alexandros Tourkolias on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:43AM CST

NBG: 2.23 (-0.11)

National Bank of Greece SA reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:21PM CST

NBG: 2.23 (-0.11)

National Bank of Greece (NBG) Stock Declines After EBA Chairman's Comments
at The Street - Thu Oct 30, 10:23AM CDT
Shares of National Bank of Greece (NBG) dropped Thursday after European Banking Authority Chairman Andrea Enria suggested last week's stress tests of European banks still left more work to do.
NBG: 2.23 (-0.11)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 8:18AM CDT

KNDI: 15.41 (-1.69), ALU: 3.16 (-0.16), CDTI: 2.65 (+0.15), VSR: 3.11 (-0.04), NBG: 2.23 (-0.11), ARAY: 6.84 (-0.01), GLUU: 3.75 (+0.04), OCLS: 1.83 (+0.07), CEMI: 4.36 (unch), TTWO: 26.11 (-0.05), PRXL: 54.24 (+0.27), RDN: 16.50 (+0.02), BBD: 14.27 (+0.17), NVAX: 5.13 (+0.18), APT: 3.27 (+0.01), BBSI: 24.37 (-0.86), LAKE: 13.08 (-0.21), GOL: 4.78 (-0.09), TASR: 18.85 (+0.33), AUY: 3.70 (-0.22), PCRX: 87.90 (+1.88), ITUB: 14.18 (+0.08)

National Bank of Greece continues slide
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 2:32PM CDT

GREK: 15.39 (-0.28), NBG: 2.23 (-0.11)

80% ECB Banks Pass Stress Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:55AM CDT
European banks emerged as healthier. Of 123 banks that were part of the stress test, only 24 failed to meet the minimum common equity ratio (CET1) level of 5.5%.
BCS: 14.89 (-0.02), SAN: 8.34 (+0.07), HSBC: 50.41 (+0.32), DB: 29.98 (-0.26), NBG: 2.23 (-0.11), RBS: 12.01 (+0.11), LYG: 4.85 (+0.03)


13 Europe banks flunk test, must find 10B euros
By DAVID McHUGH - AP - Sun Oct 26, 3:00PM CDT
FRANKFURT, Germany (AP) — The European Central Bank says 13 of Europe's 130 biggest banks have flunked an in-depth review of their finances and need an extra 10 billion euros ($12.5 billion) to cushion themselves against any future crises.
NBG: 2.23 (-0.11)


A look at European banks that flunked test
The Associated Press - AP - Sun Oct 26, 9:59AM CDT
FRANKFURT, Germany (AP) — A total of 13 European banks have been asked to strengthen their finances after a broad review of their books.
NBG: 2.23 (-0.11)

Review on Diversified Banks Stocks - US Bancorp, Banco Santander Brasil, Banco Santander, National Bank of Greece, and Comerica
PR Newswire - Fri Oct 24, 8:10AM CDT
Investor-Edge has initiated coverage on the following equities: US Bancorp (NYSE: USB), Banco Santander Brasil S.A. (NYSE: BSBR), Banco Santander S.A. (NYSE: SAN), National Bank of Greece S.A. (NYSE: NBG), and Comerica Inc. (NYSE: CMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 23, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,677.90, up 1.32% and the NASDAQ Composite closed at 4,452.79, up 1.60%. The S&P 500 finished the session 1.23% higher at 1,950.82. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Financials Sector Index ended the day at 308.34, up 0.98%, with the index advancing 4.62% on YTD basis. Register for your complimentary reports on these five stocks at:
SAN: 8.34 (+0.07), USB: 43.80 (-0.01), NBG: 2.23 (-0.11), CMA: 48.31 (-0.09), BSBR: 5.54 (+0.01)

Europe rebounds on leak of ECB support for Greece
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:11AM CDT

FEZ: 37.65 (+0.22), GREK: 15.39 (-0.28), NBG: 2.23 (-0.11)

Greek stocks plunge as bond yields soar
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 11:56AM CDT

GREK: 15.39 (-0.28), NBG: 2.23 (-0.11)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 11:47AM CDT

NPD: 1.77 (-0.05), IMDZ: 29.96 (-0.10), BCRX: 10.79 (+0.33), DLHC: 2.78 (+0.03), SWSH: 2.90 (+0.02), VSR: 3.11 (-0.04), PPHM: 1.46 (-0.09), EVRY: 1.10 (unch), DYNT: 3.90 (-0.12), NBG: 2.23 (-0.11), AMDA: 1.41 (+0.06), TRCH: 1.59 (-0.15), KTCC: 8.75 (+0.12), APT: 3.27 (+0.01), SHPG: 200.73 (+2.15), PENX: 18.78 (+0.02), LAKE: 13.07 (-0.22), MSLI: 1.50 (+0.01), COVS: 2.55 (+0.21)

Investors look to Lighten Up on Shares of National Bank of Greece, Shares Down 8.4% (NBG)
Comtex SmarTrend(R) - Wed Oct 15, 10:07AM CDT
National Bank of Greece (NYSE:NBG) is one of today's worst performing low-priced stocks, down 8.4% to $2.35 on 1.3x average daily volume. National Bank of Greece has traded 5.3 million shares thus far today, vs. average volume of 4.0 million shares per day. The stock has underperformed the Dow (-8.4% to the Dow's -1.2%) and underperformed the S&P 500 (-8.4% to the S&P's -1.2%) during today's trading.
NBG: 2.23 (-0.11)

National Bank of Greece Down 5.4%, Shares Slide into the Red (NBG)
Comtex SmarTrend(R) - Tue Oct 07, 11:36AM CDT
National Bank of Greece (NYSE:NBG) is one of today's worst performing low-priced stocks, down 5.4% to $2.63 on 1.4x average daily volume. National Bank of Greece has traded 5.4 million shares thus far today, vs. average volume of 3.9 million shares per day. The stock has underperformed the Dow (-5.4% to the Dow's -0.6%) and underperformed the S&P 500 (-5.4% to the S&P's -0.5%) during today's trading.
NBG: 2.23 (-0.11)

3 Stocks Driving The Financial Sector Higher
at The Street - Tue Sep 30, 12:04PM CDT
TheStreet highlights 3 stocks pushing the financial sector higher today.
RY: 71.63 (+0.13), RBS: 12.01 (+0.11), NBG: 2.23 (-0.11)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 225

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 308

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 412

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 130

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 288

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 131

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 127

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Expanding Horizons: Future of IVD Contract Manufacturing

Updated Category News Views 117

The Growing Landscape of IVD Contract Manufacturing The in vitro diagnostics (IVD) contract manufacturing market is on the brink of significant expansion, anticipated to reach a staggering USD 39.74 billion by 2031. This growth represents a compounded annual growth rate (CAGR) of 11.60% from 2024 to 2031, driven chiefly by the needs of the healthcare industry to keep pace...

Continue Reading
Citi Upgrades AerCap Holdings Price Target to $117 Amid Strong Performance

Updated Category News Views 79

Citi Upgrades AerCap Holdings Price Target Citi has recently updated its outlook on AerCap Holdings (NYSE:AER), raising the price target to $117 from $113. This move reflects Citi's confident stance on the aircraft leasing company's financial health within the aviation sector. By reaffirming their buy rating, the firm signals strong expectations for AerCap's growth...

Continue Reading
LG Energy Solution Reports Strong Q2 2025 Financial Performance

Updated Category News Views 750

LG Energy Solution Achieves Remarkable Financial Milestones In a significant announcement, LG Energy Solution has revealed its performance for the second quarter of 2025, detailing impressive results that demonstrate the company's resilience and strategic focus on growth. With consolidated revenue of KRW 5.6 trillion and an operating profit of KRW 492.2 billion, the...

Continue Reading
Genpact Shines as a Leader in Sustainability Recognition

Updated Category News Views 264

Genpact's Sustainable Initiatives Gain Global Recognition Recently, Genpact (NYSE: G), an advanced technology services provider, received significant acclaim for its commitment to sustainability. Being featured in TIME's prestigious list of the World's Best Companies in Sustainable Growth for 2025 showcases their dedication to ethical business practices and innovation. A...

Continue Reading
Medical Express Ambulance Faces Data Breach Investigation

Updated Category News Views 344

Understanding the Data Breach Investigation Edelson Lechtzin LLP, a prominent class action law firm, is currently looking into data privacy concerns affecting customers of Medical Express Ambulance, Inc. (MedEx). MedEx has reported potential unauthorized access to its network, raising significant alarm regarding the safety of customer data. Medical Express Ambulance, Inc....

Continue Reading